Meeting News
Advertisement
Gaurav Goyal, MD, spoke to Blood Cancers Today about strategies and guidelines for incorporating PROs into clinical trials.
Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.